India, March 11 -- Rapport Therapeutics, Inc. (RAPP) Tuesday reported net loss of $19.98 million or $0.57 per share for the fourth quarter higher than $13.52 million or $8.01 per share loss in the same quarter a year ago.
Additionally, the company said it expects to report topline data from the Phase 2a study of RAP-219 in patients with refractory focal epilepsy in the third quarter of 2025.
Rapport also plans to initiate a Phase 2a study of RAP-219 in patients with bipolar mania in the third quarter of 2025, with topline results expected in the first half of 2027.
As on December 31, 2024, the company had $305.3 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is expected to fund operations ...